Next Article in Journal / Special Issue
Molecular Insights into Poly(ADP-ribose) Recognition and Processing
Previous Article in Journal / Special Issue
Decorin Content and Near Infrared Spectroscopy Analysis of Dried Collagenous Biomaterial Samples
Biomolecules 2012, 2(4), 635-649; doi:10.3390/biom2040635
Review

Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy

 and
*
Science for Life Laboratory, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 21 Stockholm, Sweden
* Author to whom correspondence should be addressed.
Received: 12 October 2012 / Revised: 29 November 2012 / Accepted: 9 December 2012 / Published: 14 December 2012
(This article belongs to the Special Issue DNA Damage Response)
View Full-Text   |   Download PDF [455 KB, uploaded 14 December 2012]   |   Browse Figures

Abstract

Treatments with Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors have offered patients carrying cancers with mutated BRCA1 or BRCA2 genes a new and in many cases effective option for disease control. There is potentially a large patient population that may also benefit from PARP inhibitor treatment, either in monotherapy or in combination with chemotherapy. Here, we describe the multifaceted role of PARP inhibitors and discuss which treatment options could potentially be useful to gain disease control without potentiating side effects.
Keywords: DNA repair; poly(ADP-ribose) polymerase; synthetic lethality; cancer DNA repair; poly(ADP-ribose) polymerase; synthetic lethality; cancer
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote
MDPI and ACS Style

Ström, C.E.; Helleday, T. Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy. Biomolecules 2012, 2, 635-649.

View more citation formats

Related Articles

Article Metrics

Comments

Cited By

[Return to top]
Biomolecules EISSN 2218-273X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert